Today: 8 February 2026
Subscribe
Browse Category

Mergers & Acquisitions News 8 November 2025 - 12 November 2025

Baytex Energy (BTE.TO) Sells Eagle Ford Assets for US$2.305 Billion; Stock Jumps After CIRO Halt — Nov. 12, 2025

Baytex Energy (BTE.TO) Sells Eagle Ford Assets for US$2.305 Billion; Stock Jumps After CIRO Halt — Nov. 12, 2025

Calgary producer exits the U.S., refocuses on higher‑return Canadian oil plays, plans debt repayment and accelerated shareholder returns. Baytex exits the U.S. with a US$2.305B sale Baytex Energy Corp. (TSX: BTE; NYSE: BTE) said today it has signed a definitive agreement to sell all of its U.S. Eagle Ford assets to an undisclosed buyer for US$2.305 billion (about C$3.25 billion) in cash. Management framed the deal as a pivot to “a focused, high‑return Canadian energy producer,” emphasizing heavy oil, Viking light oil, and the rapidly scaling Pembina Duvernay. baytexenergy.com Use of proceeds and capital returns. Baytex intends to repay outstanding
12 November 2025
···
BILL Holdings (BILL) Surges as Company Explores a Sale — What Investors Need to Know Today (Nov. 12, 2025)

BILL Holdings (BILL) Surges as Company Explores a Sale — What Investors Need to Know Today (Nov. 12, 2025)

BILL Holdings, Inc. (NYSE: BILL) rallied today after multiple outlets reported the SMB payments platform is weighing strategic options, including a potential sale. Below is a concise rundown of what changed today, why it matters, and what to watch next. What happened today Reports of a strategic review lit a fire under BILL’s stock. Reuters said BILL concluded its shares are undervalued and is exploring a sale; talks remain preliminary with no assurance of a transaction. Bloomberg’s legal desk added that a financial adviser is soliciting interest from larger industry rivals and PE sponsors. The company hasn’t commented on the
12 November 2025
·
Clearwater Analytics (CWAN) Weighs Sale; Shares Jump as Wellington Files 6.2% Stake and New Report Flags $2.7T Insurance ‘Alts’ Shift

Clearwater Analytics (CWAN) Weighs Sale; Shares Jump as Wellington Files 6.2% Stake and New Report Flags $2.7T Insurance ‘Alts’ Shift

Clearwater Analytics Holdings, Inc. (NYSE: CWAN) is in the spotlight today after Bloomberg reported the investment‑software company is considering a potential sale following inbound takeover interest. The headline sent CWAN shares higher in Wednesday trading, coinciding with a new industry study the company released on insurers’ growing allocations to alternative assets and a fresh Schedule 13G filing showing Wellington Management as a ≥5% shareholder. SEC+3Bloomberg Law+3 Key takeaways (Nov. 12, 2025) What happened Sale interest surfaces. Bloomberg reported overnight that Clearwater Analytics “is considering a potential sale after receiving takeover interest,” citing people familiar with the matter. Such reports frequently
12 November 2025
··
CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

Creative Media & Community Trust Corporation (NASDAQ: CMCT) said it has signed a definitive agreement to sell its lending division to PG FR Holding, LLC, an affiliate of Atlanta-based Peachtree Group. The deal is expected to generate approximately $31 million in net cash for CMCT at closing and advances the company’s pivot toward multifamily growth and balance-sheet strength. Business Wire+1 Deal details: exiting SBA lender PMC/First Western CMCT is divesting First Western SBLC, Inc. (operating as PMC Commercial Trust), a national direct lender focused on SBA 7(a) loans. Peachtree said the acquisition expands its credit platform and noted PMC’s Preferred
12 November 2025
···
Amaze Holdings (AMZE) Completes The Food Channel Acquisition; Plans Platform Revamp for Culinary Creators — Nov 12, 2025

Amaze Holdings (AMZE) Completes The Food Channel Acquisition; Plans Platform Revamp for Culinary Creators — Nov 12, 2025

NYSE American–listed Amaze Holdings closed its purchase of The Food Channel, paid via a convertible promissory note, and says a refreshed FoodChannel.com will soon serve its 60,000+ food creators. Shares were among early pre‑market movers. Amaze Holdings, Inc.+1 What happened At 8:30 a.m. ET on November 12, 2025, Amaze Holdings, Inc. (NYSE American: AMZE) announced it completed the acquisition of the assets of The Food Channel, a long‑standing culinary media brand founded in 1989 that moved online in 1993 and joined the USA Today network in 2017. The deal price is $650,000 paid via a convertible promissory note. Amaze plans
12 November 2025
·
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about November 12, 2025,” pending customary conditions, including consummation of the Decoy transaction. PR Newswire Key takeaways What happened today (Nov. 12, 2025) Salarius confirmed the pricing of its offering for gross proceeds of ~$7 million before fees. The package includes: The company notes the registration statement on Form S‑1 (File No. 333‑284368) became effective on Nov. 10, 2025, and the
12 November 2025
··
Coinbase (COIN) Stock Crashes in Crypto Sell-Off – Can It Bounce Back?

Coinbase Walks Away From $2 Billion BVNK Deal as UK Weighs Strict Stablecoin Caps

Exclusive talks end without a deal, Fortune reports, while the Bank of England’s proposed holding limits draw industry fire and cloud the outlook for sterling stablecoins. Decrypt+1 Published: November 12, 2025 Key Points What Happened Coinbase has scrapped plans to acquire London-based stablecoin infrastructure firm BVNK after entering exclusive talks in October. The deal, pegged at about $2 billion, would have marked one of the sector’s larger transactions this year. A Coinbase spokesperson confirmed the breakup was mutual but did not provide a reason. Decrypt Fortune first reported the talks had collapsed; Coinbase had been seen as the front-runner after
12 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs (maximum $86.25 per share). The structure, which Metsera’s board deemed superior on value and certainty of closing, is expected to go to a shareholder vote on Nov. 13 before closing. Reuters+1 While Novo Nordisk pushed the bidding to similar headline value, meticulous antitrust calculus tipped the field. Reuters Breakingviews reports that FTC outreach helped steer Metsera toward Pfizer; coupled with
11 November 2025
··
Paramount Skydance (NASDAQ: PSKY) Jumps on First Post‑Merger Earnings: $1.5B Content Push, $3B Cost Cuts, Paramount+ Price Hike — 11/11/2025

Paramount Skydance (NASDAQ: PSKY) Jumps on First Post‑Merger Earnings: $1.5B Content Push, $3B Cost Cuts, Paramount+ Price Hike — 11/11/2025

Paramount Skydance Corporation reported its first results since the Skydance–Paramount merger and the stock rallied after management laid out a bigger streaming-and-studios investment plan and raised its cost‑savings target. Shares were up ~5.5% today as CEO David Ellison emphasized a tech‑forward overhaul, a fatter content slate, and a sharper path to profitability. Reuters Quick take (today) What happened on November 11, 2025 Stock reaction & strategy. Investors bid PSKY higher after management raised its savings target to $3B, laid out >$1.5B in incremental 2026 programming investments, and reiterated a push to unify streaming platforms and ramp to ~15 theatrical releases
11 November 2025
··
Kaltura (KLTR) soars as Q3 beats, $27M eSelf.ai deal lands, and 14.4M-share buyback headlines — Nov. 11, 2025

Kaltura (KLTR) soars as Q3 beats, $27M eSelf.ai deal lands, and 14.4M-share buyback headlines — Nov. 11, 2025

What’s new today (Nov. 11, 2025) Shares surge after Q3 + AI deal headlines. KLTR is one of today’s bigger software movers. Benzinga’s pre‑market screen flagged KLTR up ~26.5% to $1.86 before the bell following last night’s results and acquisition news; live prices show the rally continuing after the open. Benzinga Local tech press amplifies the acquisition. Israeli outlet CTech detailed the $27M structure (including 4.69M Kaltura shares vesting over three years—about 3% of pre‑deal share base) and reiterated that closing is targeted for Q4 2025, pending approvals. TechCrunch highlighted co‑founder Dr. Alan Bekker’s prior sale of Voca.ai to Snap
11 November 2025
···
C3.ai (AI) shares edge higher as company explores sale — everything new on November 11, 2025

C3.ai (AI) shares edge higher as company explores sale — everything new on November 11, 2025

C3.ai, Inc. (NYSE: AI) is in the spotlight today after a late‑Monday Reuters exclusive said the enterprise‑AI software maker is exploring a potential sale as part of a broader strategic review following its recent leadership transition. Additional outlets echoed the report overnight in Asia and Europe, and traders are watching for follow‑on headlines ahead of the company’s next earnings date in early December. reuters.com+2thestar.com.my+2 The latest (Nov 11, 2025) Why this development matters What industry watchers are saying today Key dates and what to watch next Background: the road to today Quick FAQ (today’s essentials) Is C3.ai being sold?Not necessarily.
11 November 2025
···
Shiseido cuts 2025 outlook to ¥52bn net loss, books ¥46.8bn Americas impairment and launches 200‑person voluntary exit

Shiseido cuts 2025 outlook to ¥52bn net loss, books ¥46.8bn Americas impairment and launches 200‑person voluntary exit

Tokyo — November 10, 2025 Japan’s Shiseido Co. (TSE: 4911) slashed its full‑year guidance and flagged deeper restructuring, warning it now expects a ¥52 billion net loss for the year to December 31, 2025 (IFRS), versus a previous forecast for a ¥6 billion profit. The cosmetics group cited a goodwill impairment in the Americas and softer demand as it also unveiled a new medium‑term strategy through 2030. Shiseido Corporation+1 What Shiseido announced today Japanese media also highlighted the scale of the forecast swing and the impairment behind it. Kabutan+1 Restructuring: 200 voluntary retirements, after earlier headcount cuts Shiseido will offer
10 November 2025
Axia Energia debuts AXIA3; court declares Oi bankrupt; Kepler Weber gets R$11 offer — Brazil market wrap (Nov 10)

Axia Energia debuts AXIA3; court declares Oi bankrupt; Kepler Weber gets R$11 offer — Brazil market wrap (Nov 10)

São Paulo — November 10, 2025. Key points Axia Energia: new tickers on B3 and NYSE Axia Energia—Eletrobras’ new name—debuted its tickers on B3 this Monday: AXIA3 (common), AXIA5 (preferred A) and AXIA6 (preferred B). On the NYSE, the company’s ADRs now trade as AXIA (common) and AXIA PR (preferred), replacing EBR and EBR.B. Axia marked the change with a bell‑ringing ceremony at B3 around 9 a.m. (Brasília). At 10:45 a.m., AXIA3 rose 1.84% to R$59.76 while AXIA6 advanced 1.57% to R$62.92. InfoMoney B3’s own investor portal Bora Investir confirms the new codes and trading name (“AXIA ENERGIA”). A Citibank
10 November 2025
····
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure. Key takeaways (Nov. 10) What changed today The revised terms, line by line (from today’s 8‑K) Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement: Why Novo bowed out — and the FTC’s
10 November 2025
·
Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

What Happened Movano Inc. (NASDAQ: MOVE) and Corvex, Inc., a GPU‑accelerated AI cloud company, signed a definitive all‑stock merger agreement. The combined business will focus squarely on secure, high‑performance AI infrastructure—including GPU clusters for training/inference, confidential computing, and inference‑as‑a‑service—repositioning Movano away from consumer health wearables. Upon closing, “Movano Inc.” will be renamed “Corvex, Inc.” and move its headquarters to Arlington, Virginia. PR Newswire The boards of both companies have unanimously approved the transaction, which is targeted to close in Q1 2026, subject to customary approvals, Nasdaq listing conditions for the new shares, and the effectiveness of an S‑4 registration statement.
10 November 2025
··
Ondas Holdings (ONDS) names ex‑Rafael chief Yoav Har‑Even to OAS advisory board as Sentrycs acquisition advances — Nov. 10, 2025

Ondas Holdings (ONDS) names ex‑Rafael chief Yoav Har‑Even to OAS advisory board as Sentrycs acquisition advances — Nov. 10, 2025

Ondas Holdings Inc. (NASDAQ: ONDS) announced that Maj. Gen. (Ret.) Yoav Har‑Even, former President & CEO of Rafael Advanced Defense Systems, has joined the advisory board of Ondas Autonomous Systems (OAS), the company’s defense and security robotics unit. The move adds a veteran of multi‑domain operations and large defense programs to OAS at a time when Ondas is expanding its counter‑UAS and autonomous platforms portfolio. Ondas Holdings Inc. What happened today Stock snapshot As of early afternoon (14:11 UTC) on Monday, ONDS traded around $5.81, up ~10.5% on the day. Why this matters The Har‑Even appointment signals Ondas’ intent to
10 November 2025
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board intensified as Norway’s $1.5 trillion sovereign wealth fund said it would abstain from key votes this week. Separately, Novo struck a distribution pact in India to sell a new branded version of its semaglutide weight‑loss shot. Reuters+3Reuters+3Reuters+3 Key takeaways How NVO and PFE are trading today Pfizer seals Metsera deal: what’s in it and why it matters Pfizer’s agreement to
10 November 2025
Pandox Completes €1.7bn Dalata Takeover: Dalata Delists Today as Scandic Takes Over 56 Hotels (10 Nov 2025)

Pandox Completes €1.7bn Dalata Takeover: Dalata Delists Today as Scandic Takes Over 56 Hotels (10 Nov 2025)

Published: 10 November 2025 Summary: Dalata Hotel Group plc has been formally delisted this morning following the completion of its acquisition by a Pandox AB–Eiendomsspar AS consortium. Scandic Hotels Group has begun managing Dalata’s 56 hotels under an interim management agreement and intends to acquire the operating platform for €500 million after a carve‑out, while Pandox will retain 31 investment properties in Ireland and the UK under long‑term, revenue‑based leases once the separation is complete. pandox.se+3pandox.se+3Investegate+3 What changed today (10 November 2025) Deal at a glance Scandic’s role: manage now, buy later Effective 7 November 2025, Scandic assumed operational responsibility
10 November 2025
··
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Financing & balance sheet: euro notes + tender offer Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. Bristol Myers Squibb News Proceeds, plus about $3B in cash, are earmarked to fund BMS’s cash tender offers for multiple outstanding dollar notes. The offers expire Dec. 3, 2025 (early tender Nov. 17), with maximum aggregate purchase prices of $4B (Pool 1) and $3B (Pool 2) excluding
9 November 2025
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next. Updated: November 8, 2025 Top takeaways What changed on Nov. 7–8 Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of $65.60 per share in cash and a contingent value right of up to $20.65). The board unanimously reaffirmed its support for Pfizer’s deal, citing both superior certainty of closing and “unacceptably high legal and regulatory risk” tied to Novo’s competing
8 November 2025
·
1 … 13 14 15 16 17 … 20

Stock Market Today

CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom

CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom

8 February 2026
Commonwealth Bank of Australia closed Friday down 0.23% at A$158.91, outperforming a 2.03% drop in the S&P/ASX 200. Investors await CBA’s half-year results on Feb. 11 and commentary from CEO Matt Comyn. The Reserve Bank’s recent cash-rate hike to 3.85% and upcoming mortgage repricing are in focus. CBA flagged A$68 million in provisions and A$53 million in non-recurring income items.
Boeing stock jumps 2.6% to $243 — what Wall Street is watching before Monday

Boeing stock jumps 2.6% to $243 — what Wall Street is watching before Monday

8 February 2026
Boeing shares closed up 2.6% at $243.03 Friday, buoyed by reports of possible major aircraft orders from Saudi Arabia and India. India’s trade minister said a $70–80 billion Boeing deal could be signed by March. Supply-chain delays and regulatory scrutiny remain key risks. Boeing’s chief engineer sold over 10,000 shares earlier in the week.
Go toTop